Reading Time: 2 minutesOn Friday 5 May in America, the FDA, the organisation that approves drugs, announced that they’d granted a licence for the drug known as a
Category: Treatments
27th Symposium: Dublin 2016 Causes and disease mechanisms Clinical Trials MND Research News Symposium
Prize winning posters in Dublin
Reading Time: 4 minutesAs well as all the networking, debate and new information being shared, the International Symposium on ALS/MND is also a time to celebrate achievements by
Reading Time: 2 minutesA few months ago we wrote an article about the ALS Clinical Trials Workshop which took place in Virginia, USA. Since then the Guidelines Working
Reading Time: 2 minutesPrevious research in humans and zebrafish has shown that before symptoms arise in MND, early changes occur in the interneurones. This type of nerve cell
Reading Time: 2 minutesDuring the early stages of MND it is proposed that motor neurones are more susceptible to an imbalance of oxygen within the cells, known as
Reading Time: 2 minutesIf you looked at the motor neurones of people with MND down the microscope you would see clumps of a protein called TDP-43. Researchers around
Reading Time: 2 minutesDeveloping disease models is important for furthering our understanding of MND and allows researchers to screen potential new drugs for a beneficial effect. Moving a
Reading Time: 2 minutesDeposits of the protein TDP-43 are found within the motor neurones in the majority of cases of MND, and are considered a pathological hallmark of
Reading Time: 3 minutesTo mark International Clinical Trials Day (20 May) we reflect on the ALS Clinical Trials Guidelines workshop that took place in March. The MND Association
Reading Time: 4 minutesThe recent announcement about the use of stem cells to treat a form of multiple sclerosis (MS), together with early results from the BrainStorm stem